Skip to content

Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human

Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01131533
Enrollment
5
Registered
2010-05-27
Start date
2009-01-31
Completion date
2011-12-31
Last updated
2010-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythropoietin, Pharmacokinetics

Brief summary

The investigators investigate intraocular concentrations and pharmacokinetics of erythropoietin after a single intravitreal injection in humans.

Detailed description

Intravitreal injections of erythropoietin for off-label use have been shown to be beneficial in eyes with diabetic macular edema.However, the pharmacokinetic profile of erythropoietin after intravitreal injection in humans has not yet been determined clearly. The purpose of this study was to determine the intraocular pharmacokinetics of erythropoietin after a single intravitreal injection in a prospective investigation.

Interventions

PROCEDUREVitrectomy

vitrectomy following intravitreal erythropoietin

Sponsors

Hallym University Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diabetic macular edema that failed to respond to or recurred after the previous macular focal laser photocoagulation or intravitreal therapy, or both. * visual acuity worse than 40/200 snellen bisual acuity

Exclusion criteria

* Eyes with vitreomacular traction, active proliferative diabetic retinopathy, intraocular inflammation, uncontrolled intraocular pressure , cataract surgery within the past six months, or a prior history of vitreoretinal surgery

Design outcomes

Primary

MeasureTime frameDescription
Concentration of erythropoietin in aqueous humora few secondserythropoietin injections had been performed in our department following standard procedures. In selected cases,vitrectomy was performed one to two days after erythropoietin injection to treat diabetic macular edema.During surgery, aqueous humor samples were obtained via a corneal paracentesis anterior to the limbus at the beginning of the procedure.

Secondary

MeasureTime frameDescription
Concentration of erythropoietin in vitreousfew minuteserythropoietin injections had been performed in our department following standard procedures. In selected cases,vitrectomy was performed one to two days after erythropoietin injection to treat diabetic macular edema.During surgery, vitreous samples were obtained via vitreous cutter at the beginning of the procedure.

Countries

South Korea

Contacts

Primary ContactJiWon Lim
jiwoneye@hallym.or.kr82-33-240-5176

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026